Protocol Ledger

NCT07527858 · Phase II · RECRUITING

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Interventional Phase II clinical trial protocol NCT07527858 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-19 Enrollment: 170 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07527858
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)170 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07527858
Protocol FieldVerified Registry Value
NCT IdentifierNCT07527858
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment170 participants (ESTIMATED)
Registered Start Date2026-05-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI